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Type B aortic dissections continue to be one of the most challenging clinical scenarios confronting vascular surgeons. In
the era of open surgery, the therapeutic options were limited to medical management of hypertension and large open
thoracoabdominal operations. In the current endovascular era, the operative strategies have become less invasive but the
questions regarding therapeutic approaches have become more numerous and complex. In patients with acute uncom-
plicated type B aortic dissections, we are still unsure as to which patients are best treated with medical therapy alone or
with the addition of early endovascular repair. Data from single centers and registries have provided some guidance;
however, questions remain. Perhaps level 1 evidence from well-designed randomized controlled trials will answer all of
our questions. This is the topic of the current debate. (J Vasc Surg 2013;58:836-42.)PART I: LEVEL I EVIDENCE COMPARING
THORACIC ENDOVASCULAR REPAIR AND
MEDICAL MANAGEMENT IS NECESSARY
FOR UNCOMPLICATED TYPE B AORTIC
DISSECTIONS
JanBrunkwall,MD, andThomasLübke,MD,Cologne,
Germany
Before we go into the debate, some basic information
needs to be provided. Dissection of the aorta is a life-
threatening disease and is considered as “acute” when the
diagnosis is made within 2 weeks of the initial symptoms.
The deﬁnition of an acute dissection is not uniform in
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are included.1 Acute dissection of the ascending aorta
(DeBakey I or II or Stanford A), with an assumed mortality
rate of 1%-2% per hour in the ﬁrst 24 hours after symptom
onset, requires a prompt surgical therapy.2-4 Medical
therapy alone in this setting is associated with 50%
mortality at 30 days in older series2 and has been reported
to be lower with surgery.5 However, there is no evidence
based on randomized controlled trials (RCT) or compara-
tive studies to answer this question. According to the Inter-
national Registry of Acute Aortic Dissection (IRAD),
dissection of the aorta occurs in the descending aorta (DeBa-
key III or Stanford B) in about 37% of the patients.4 The
data from IRAD is currently setting a trend on the views
of the acute dissection, both for type A and type B. This
important register is multicentered and has gathered
numerous patients, adding very useful information such as
predictors for mortality and complications. On the other
hand, several questions cannot be answered by this registry
(ie, howmany of the uncomplicated dissections will become
complicated and how standardized the different therapy
options are.) No information is provided regarding hyper-
tension control. These are extremely important questions
for initial decision making. Although acute type B dissection
carries a lower initial overall mortality than type A dissections
with about 10% deaths within 30 days, the diagnosis can be
difﬁcult and sometimes even delayed because of multiple
possible symptoms. The outcome of type B dissections is
related to the clinical presentation and can be worsened by
severe life-threatening complications. The most common
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into the ascending aorta, refractory pain, and in the long run,
aortic dilatation and aneurysm formation.6,7 Occurrence of
at least one of those conditions, thus, makes a dissection
“complicated.”About 30% of acute type B aortic dissections
are complicated by peripheral vascular ischemia or hemody-
namic instability, with a subsequent high risk of death,8-11
but we do not know which patient will have these complica-
tions. In addition to these early complications, aneurysmal
evolution occurred within 5 years in 20%-50% of the patients
who had survived the acute phase,11,12 and these are the
complications that we are aiming to prevent. IRAD data
showed that the most common cause of death was rupture
(40%) followed by intestinal ischemia (17%-39%).5
Although not scientiﬁcally proven, but based on good
clinical practice, there is a general agreement that patients
with an initially uncomplicated type B aortic dissection
should receive medical therapy with close monitoring of
the blood pressure to decrease the shear forces on the aortic
wall. The basic medical treatment comprises b blockers,
diuretics, calcium blockers, and angiotensin-converting
enzyme inhibitors with in the acute phase additional alpha
blockers as well as nitroglycerin. The primary aim of this
approach is to obtain a systolic blood pressure between
100 to 120 mm Hg with the maintenance of a urinary
output and prevention of malperfusion of the visceral
organs. In a series of 171 cases of acute type B aortic dissec-
tions with a median follow-up of 2.3 years, Kodama et al13
found that, although use of b blockers did not itself affect
outcomes, heart rate control was associated with a signiﬁcant
reduction of overall aortic complications (12.5% vs 36% in
controls). Meanwhile, current data revealed a mortality
rate of medically treated type B aortic dissections of around
10%within the ﬁrst month. From the IRADdata, it could be
concluded that calcium channel blockers were correlated
with a better survival during follow-up in type B aortic
dissections, whereas b blockers improved the outcome after
surgery for type A aortic dissections.14,15 These conﬂicting
data need to be clariﬁed by future RCT using b blockers
and calcium channel blockers in patients having only type
B dissections, leaving the type A dissection patients for
a separate study.
The same confusion exists when addressing the long-
term survival of patients with type B aortic dissections. In
this context, only one publication from Sweden has shown
that after surviving the ﬁrst month, the long-term survival
was not different from that of the general population,16
whereas other authors have reported a signiﬁcant number
of complications with 48%-82% survival at 5 years. IRAD
data have conﬁrmed this trend by showing that 189
consecutive patients with acute type B aortic dissection,
who were successfully discharged alive following medical
therapy, had a 3-year survival of 78%.17 In this setting,
25%-50% of patients treated medically will develop late
aortic-related complications with the need for an endovas-
cular or open repair. Thus, we are lacking reliable informa-
tion on the survival of patients with type B dissections.Endovascular repair is a well-known alternative to open
repair for the treatment of abdominal aortic aneurysm sup-
ported by the two initial European prospective randomized
trials (Dutch Randomised Trial on Endovascular Versus
Open Aneurysm Repair [DREAM], Endovascular Aneu-
rysm Repair [EVAR]).18-20 Accordingly, but despite the
lack of RCT, the use of stent grafts has been introduced
to and reported favorable in thoracic aortic aneurysms
and in traumatic thoracic aortic ruptures.21-23 Since the
ﬁrst report of thoracic endovascular repair (TEVAR) in
aortic dissections by Dake et al in 1999,24 several cohort
studies have demonstrated its feasibility and efﬁcacy.
However, so far, there is no RCT of TEVAR for the treat-
ment of acute complicated type B dissection, although
nonrandomized studies suggest a lower mortality rate
compared with open surgery.24-26 It is true that the
results of stents or fenestration procedures for treating
vascular malperfusion caused by type B aortic dissection
are encouraging with respect to vessel patency but not to
mortality.27-30 However, all these series are retrospective
and without a control group of patients, and subsequently,
their scientiﬁc evidence is low.
We have shown in our updatedmeta-analysis of TEVAR
for predominantly acute uncomplicated type B aortic dissec-
tions an average weighted 30-day mortality of 10.0% (68
studies, totaling 1685 patients), and a late mortality with
a weighted average event rate of 11% (63 studies, totaling
1609 patients), suggesting that TEVAR may be beneﬁcial
in these cases as well. Our meta-analysis of four single-arm
studies with a total of 501 patients regarding best medical
treatment (BMT) for uncomplicated type B aortic dissec-
tions showed an average weighted rate for late mortality
or late complications of 13.8% and a 30-day mortality of
11% (seven studies, totaling 962 patients). However, one
could not use these data as evidence-based because the
numbers are small and a control group is lacking.
Another meta-analysis of four nonrandomized studies
each comparing TEVAR with BMT for complicated type
B aortic dissection (totaling 292 patients with medical
treatment and 141 patients with TEVAR) showed no
signiﬁcant difference between the two therapeutic options.
Again, these data are of limited value because of the limited
number of patients and the nonrandomized study design.
Regarding uncomplicated chronic type B aortic dissec-
tion, the results of a randomized trial comparing TEVAR
with BMT after 2 weeks were recently published (Investi-
gation of Stent Grafts in Aortic Dissection [INSTEAD]
trial).31 This trial showed that when the stent graft was
placed between 2 weeks and 1 year after the onset of the
acute dissection, TEVAR did not do better than BMT on
the 2-year all-cause or aortic-related mortality. Even if
underpowered for mortality, the INSTEAD trial has shown
that there was a remodeling of the aorta leading to an
enlarged true lumen with regression of the false lumen.
Aortic remodeling with thrombosis of the thoracic false
lumen occurred in 91.3% of patients with TEVAR vs
19.4% of patients with BMT.
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vulnerable dissected aorta, but the INSTEAD trial clearly
showed that TEVAR was not associated with a higher
mortality than BMT in chronic uncomplicated type B aortic
dissection. We are awaiting the publication of the long-term
follow-up results, which when orally presented, have shown
a better survival of the TEVAR group compared with the
BMT group. Accordingly, TEVAR might be a better thera-
peutic option than BMT alone for 20%-30% of patients with
uncomplicated type B aortic dissection that will develop an
aneurysmal dilatation of the false lumen, requiring late
surgical intervention. The reason might be found in the
hazard of having a patent false lumen that was described
by Akutsu et al who found a higher mortality rate in patients
having a patent false lumen than in those having a throm-
bosed one.32 In this setting, a multivariate analysis has
shown that baseline maximum descending aortic diameter,
proximal location, and size of the entry tear were predictors
of related adverse events, whereasmortality was predicted by
the maximum diameter of the descending thoracic aorta,
entry tear size, and Marfan syndrome.33 These results
again underscore the need for a prospective RCT to study
the long-term result of TEVAR þ BMT vs BMT alone in
these patients with a type B aortic dissection.
Following the review of the available data, what
evidence-based concept do we have for the treatment of
acute uncomplicated type B dissection? Absolutely none!
All our knowledge is based on a large but heterogeneous
registry of type A and B dissections, whose results demon-
strate the risk of false lumen enlargement, and one RCT on
chronic uncomplicated type B dissections showing the
safety of TEVAR for treating the dissected aorta, leading
to thrombosis of the false lumen. What advantage does it
have to treat a dissection in the ﬁrst 2 weeks after the initial
event where no remodeling processes and stabilization of
the aortic wall layers have occurred? Covering the entry
tear of acute type B dissections and thereby causing
a thrombosis of the false lumen in an early phase of the
disease could be the solution to avoid late lumen enlarge-
ment as well as treating some malperfusion complications
as observed in our own clinical practice.
Until now, there is no level I evidence to support the
routine use of TEVAR for DeBakey III dissections, and
there is no level I evidence for the medical treatment either.
The need for interventions in uncomplicated type B aortic
dissections is characterized by a paucity of relevant data,
most of them being derived from TEVAR in complicated
aortic dissections, where mortality for TEVAR is in the
same range as BMT for uncomplicated dissections. But
are we comparing the same patients? It is likely that the
two cohorts are very different. Furthermore, the treatment
paradigm still under use, which advocates intervention only
in the complicated cases, is derived from those times when
open surgery had a worse risk-to-beneﬁt ratio compared
with medical therapy. Today with the evolution of
TEVAR, and improved stent grafts, standardization of
TEVAR might shift the risk-to-beneﬁt ratio in favor of
early intervention. Nevertheless, this needs to bescientiﬁcally proven. The European study, Acute Dissec-
tion: Stent Graft or Best Medical Treatment (ADSORB),
which evaluates TEVAR þ BMT vs BMT alone in patients
with acute uncomplicated type B aortic dissection, has
completed its enrollment, and its results are urgently
needed to determine the best way to treat this potentially
lethal disease.34
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PART II: LEVEL I EVIDENCE COMPARING
THORACIC ENDOVASCULAR REPAIR AND
MEDICAL MANAGEMENT IS NOT NECESSARY
FOR UNCOMPLICATED TYPE B AORTIC
DISSECTIONS
Adam H. Power, MD, MPhil (Cantab), and
Thomas L. Forbes, MD, London, Ontario, Canada
Be it resolved that we do not need level 1 evidence
comparing best medical treatment (BMT) with thoracicendovascular repair (TEVAR) in patients with uncompli-
cated type B aortic dissection (BAD). There is reasonable
level 1 evidence available for subacute/chronic type B
dissection (Investigation of Stent Grafts in Aortic Dissec-
tion [INSTEAD] trial1), and we concede that the long-
term results of this trial are needed to help clarify initial
ﬁndings. We will argue instead that level 1 evidence for
acute uncomplicated BAD, and consequently the Acute
Dissection: Stent Graft or Best Medical Treatment
(ADSORB) trial,2 was not required, nor has it resulted in
clinically applicable information. Rather than focusing on
whether all BADs should be treated with TEVAR or not,
we need to determine which group of patients will ﬁnd
the most beneﬁt. We are well on our way to understanding
this without the need of a randomized trial.
One core issue in the study of BADs is that many of its
features are not uniformly deﬁned. The only generally
agreed upon deﬁnition is that Stanford type B or DeBakey
III aortic dissection originates in the descending thoracic
aorta without retrograde extension into the ascending
aorta. BADs are considered complicated if they involve
malperfusion or rupture, but studies are inconsistent on
whether to include other symptoms such as refractory
hypertension and persistent pain.3 Imaging ﬁndings such
as an increase in periaortic hematoma and hemorrhagic
pleural effusion clearly increase morbidity and mortality
but are inconsistently reported.4 Historically, BAD is
considered acute when it occurs within 14 days of
symptom onset whereas a dissection discovered after 2
weeks is considered chronic. In recent years, the term
“subacute” has been used, further confounding the
temporal classiﬁcation. The INSTEAD trial is the only
randomized controlled trial (RCT) of subacute or chronic
type B dissections treated with TEVAR plus BMT vs BMT
plus surveillance.1 Conversely, the ADSORB trial, whose
1-year results have recently been published, is the only
RCT of acute type B dissections treated with TEVAR
plus BMT vs BMT.2 BMT generally involves lowering
patients’ blood pressure to approximately 120 mm Hg
systolic over 80 mm Hg diastolic. Beta blockade is usually
ﬁrst line therapy and is supplemented by diuretics, angio-
tensin-converting enzyme inhibitors, calcium channel
blockers, and sometimes alpha blockers in refractory
cases.5-7 TEVAR involves endograft coverage of the dissec-
tion entry tear.
There is overwhelming evidence, albeit mostly from
nonlevel 1 data, that patients with uncomplicated acute
BADs do well with BMT.6,8 In the International Registry
of Acute Aortic Dissection (IRAD) study, this has resulted
in a 10% 30-day mortality.9 The INSTEAD trial, which
looked at subacute/chronic BADs, garnered even better
results with BMT having a 2-year cumulative survival rate
of 95.6% 6 2.5%.1 For clinical equipoise to occur, and
thus make an uncomplicated acute BAD RCT clinically
relevant, one must be convinced that there is no superior
treatment or, in other words, that TEVAR is equivalent
or better than BMT. We need to look no further than
the ADSORB trial to show that clinical equipoise has not
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low recruitment. As other critics have pointed out, the
slow recruitment with ADSORB necessitated a power
recalculation to permit study completion but resulted in
the study being underpowered to demonstrated differences
in aortic-related or all-cause mortality.10 Even though the
mortality in acute uncomplicated BAD is highest in the ﬁrst
10-14 days, if we can achieve a 90% 30-day survival rate
without intervention, just how many patients do we expect
to beneﬁt in the short term from TEVAR? Moreover, the
patients at risk for developing complications with BMT
are unlikely to be completely protected with TEVAR and
are no doubt the same patients who would have technically
difﬁcult TEVAR procedures leading to higher morbidity
and mortality.
Level 1 evidence really is not achievable because of the
inability to obtain conventional and clinically relevant
endpoints. One of the main criticisms of the INSTEAD
trial is that it was underpowered to detect mortality at 2
years, which was its primary outcome and arguably one
of the few outcomes that might change clinical practice.11
Similarly, the ADSORB trial was not powered to identify
a mortality difference. To do so, it would have required
much larger numbers of patients recruited over many years,
which was simply not feasible. The ADSORB trial’s
composite primary endpoint of false lumen thrombosis,
aortic dilation at 1 year, and aortic rupture through to 1-
year follow-up is unlikely to alter our understanding of
the treatment of BAD. Looking at their results, there has
been much emphasis on a statistically signiﬁcant increase
in true lumen diameter and decrease in false lumen diam-
eter at 1 year (P < .001), despite there being no overall
change in maximal diameter of the descending thoracic
aorta.2 Indeed, inducing false lumen thrombosis and aortic
remodeling has been shown in some studies to have
improved patient outcomes over time,12,13 but they are
scarcely the hard endpoints that we need in a randomized
trial to change clinical practice. Treating all acute BADs
with TEVAR to promote favorable aortic remodeling is
akin to repairing all small abdominal aortic aneurysms to
prevent aneurysm dilation.
In the end, even when the long-term results of
ADSORB are completed and published, they will not solve
the questions that we need answered. Rather than
a randomized trial that attempts to tell us whether TEVAR
or BMT is best for all uncomplicated acute type B dissec-
tions, we need a study that tells us which dissections will
become complicated and, thus, need TEVAR. The
INSTEAD trial has shown that a complication-speciﬁc
approach for subacute/chronic dissections rather than
a blanket TEVAR approach is likely best.11 Risk factors
are emerging from IRAD data and other studies to help
better identify the patients who might beneﬁt from early
TEVAR. Sex, ethnicity, underlying connective tissue disor-
ders, intramural hematoma, false lumen patency or partial
thrombosis, early dilation, smaller diameters at presenta-
tion, and even visceral and renal artery involvement allinﬂuence the risk of subsequent aortic dilation.4,14 Further-
more, as diagnostic imaging continues to improve and our
use and understanding of computational ﬂuid dynamics
increase, we come closer to deﬁning a BAD population
who might truly beneﬁt from intervention.15 Until we
more accurately identify these patients and achieve the clin-
ical equipoise required for an RCT, attempting to attain
level 1 evidence for the treatment of all uncomplicated
BADs is not needed.
As the ADSORB trial has unfortunately shown, it is not
possible to perform a sufﬁciently powered RCT with clini-
cally relevant endpoints comparing TEVAR and BMT in
acute BADs in a timely fashion. It took 10 years for
ADSORB to complete recruitment to deliver an under-
powered study with a power recalculation and a composite
endpoint. Further information is required regarding which
acute dissections require TEVAR. However, such an area is
where properly performed registries have clear advantages
over the “level 1” evidence that RCTs provide.
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strated superiority over medical treatment for patients with
uncomplicated type B aortic dissection.1 In this clinical setting,
rupture is uncommon except in cases with a large aneurysm at
the entry site or large false lumen dilatation. However, aortic
branch occlusion by the propagation of the false lumen and subse-
quent malperfusion syndrome may complicate the initial presenta-
tion. Until now, a complication-speciﬁc approach has been
adopted as the standard of care, but endovascular treatment
(TEVAR) sealing the aortic tear and achieving depressurization
of the false lumen has the potential to reduce both early and late
complications and to change treatment strategies. However, as
explained by our debaters, many questions remain and it is not
clear if we need more evidence before accepting TEVAR as routine
in these patients with uncomplicated type B aortic dissection.
UNCOMPLICATED ACUTE TYPE B AORTIC
DISSECTION
Meta-analysis2 of three studies comparing medical therapy and
TEVAR for acute uncomplicated type B aortic dissection3-5 found
a lower early mortality rate with medical therapy compared with
TEVAR (odds ratio, 0.50; 95% conﬁdence interval, 0.27-0.95).
In three other studies comparing TEVAR and open surgery,5-7
the pooled early mortality rate was signiﬁcantly higher for open
surgery (odds ratio, 2.66; 95% conﬁdence interval, 1.37-5.17).
However, in these nonrandomized studies, comparison of medical
therapy vs TEVAR or vs open surgery for acute uncomplicated
type B aortic dissection is often biased with an overestimation of
low complication rates in patients at lower risk and usually assigned
to medical therapy. Nevertheless, according to these data, there is
evidence, although not from level 1 studies, that patients with
uncomplicated acute type B aortic dissection do well with medical
treatment alone.2 This strategy was debated by Jan Brunkwall who
supports the use of TEVAR in acute type B aortic dissection
following data from the Acute Dissection: Stent Graft or Best
Medical Therapy (ADSORB) study8 showing that TEVAR allows
true lumen expansion. However, in this trial, low recruitment
resulted in an underpowered study not being able to demonstrate
a potential difference in mortality between the two groups.
UNCOMPLICATED CHRONIC TYPE B AORTIC
DISSECTION
Regarding chronic type B aortic dissection, the Investigation of
Stent Grafts in Patients with Type B Aortic Dissection (INSTEAD)
randomized controlled trial (RCT)9 showed that medical therapy
with close surveillance was associated with excellent all-cause and
aorta-related survival rates that were not improved by TEVAR. In
detail, the survival rate at 2 years was 88.9% 6 3.7% with TEVAR
vs 95.6% 6 2.5% with medical treatment (P ¼ .18). Similarly, the
aorta-related 2-year survival was comparable among the two
groups. As discussed by our debaters, with 11 deaths, the 2-year
death rate did not meet the assumption of 28 events for statisticalpower. Finally, the cluster end point of aorta-related death, cross-
over/conversion, and ancillary procedures was not statistically
different between the two groups with freedom from event in
72.5% 6 5.5% of the patients with medical treatment vs 77.2% 6
5.0% for TEVAR (P ¼ .65). It should be emphasized that in this
RCT, most patients were randomized 2 weeks after the onset of
symptoms; thus, those with early complications, who would most
likely beneﬁt from TEVAR, were not included in the study cohort.
In addition, among the seven patients who died in the TEVAR
group, four of themwithmalperfusion or impending rupture should
have been excluded from this RCT aimed at electivemanagement of
uncomplicated chronic type B aortic dissection.10 Despite these
criticisms, INSTEAD, the only RCT for chronic type B aortic
dissection supports a complication-speciﬁc approach instead of the
routine use of TEVAR. However, some encouraging data were
also reported in this trial showing aortic remodeling at 2 years
with true lumen recovery and false lumen thrombosis in 91.3% of
patients receiving TEVAR vs 19.4% of patients in the medical
group. This was not the end point of the study, but aortic remodel-
ing may be considered a surrogate for prevention of late aneurysm
formation.11
After an extensive review of the literature, our debaters
proposed different strategies and we suggest that medical manage-
ment with close imaging follow-up is probably the best strategy for
uncomplicated type B aortic dissection. However, as demonstrated
by our debaters, the evidence favoring this strategy is thin. Consid-
ering the lack of power of the ADSORB and INSTEAD trials, we
need large studies on type B aortic dissection stratiﬁed by type and
timing with long-term follow-up to provide optimal treatment
guidelines.
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